Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Eligibility criteria

Qualifiers

Age >18 years old.

The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.

Patients or their families agreed to participate in the study and authorized informed consent.

Disqualifiers

Incomplete clinical data.

Do not agree to the inclusion or refuse to authorize the informed consent.

Trial design

Treatments tested in this trial

  • Diagnosis of ACM

Treatment groups

1,500 Participants
are divided into 3 treatment groups